SAN ANTONIO (AP) - One of the most promising new approaches for fighting breast cancer took a stunning setback Thursday when a major study showed that a bone-building drug did not stop cancer from ...

Zoledronic acid, a drug currently approved for osteoporosis treatment, has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as a supplemental therapy in ...

A brief discussing findings from this year's San Antonio Breast Cancer Symposium showing that research suggests that the drug Zometa may provide patients with reduced bone loss and a lesser chance of ...

A new drug called denosumab may soon give Zometa (zoledronic acid) competition as the standard of care in treating bone metastases in patients with advanced breast cancer. Patients taking denosumab ...

— -- A bone-building drug also may help certain women with early breast cancer, a study shows. Breast cancer patients who took the drug Zometa, in addition to hormonal therapy, were 35% less ...

November 1, 2011 — In postmenopausal breast cancer patients, bisphosphonates are commonly used to counter the adverse effects of aromatase inhibitors (AIs) on bone. Now there is a suggestion that the ...

CHICAGO (Reuters) - The Novartis bone-strengthening drug Zometa may enhance the effects of chemotherapy, shrinking breast tumors and helping more women avoid a mastectomy, British researchers said on ...

NEW YORK, Dec 9 (Reuters) - The Novartis osteoporosis drug Zometa failed to improve disease free survival of early breast cancer patients in a large clinical trial, but some benefit was observed in ...

5/31/2008 CHICAGO It is the first large study to affirm wider anti-cancer hopes for Zometa and other bone-building drugs called bisphosphonates. Zometa, made by Novartis AG, is used now for cancers ...

However, the drug Zometa did seem to help certain post-menopausal women. Its maker, Novartis AG, is considering further study, but will suspend plans to expand it beyond its current use as a treatment ...

CHICAGO It is the first large study to affirm wider anti-cancer hopes for Zometa and other bone-building drugs called bisphosphonates. Zometa, made by Novartis AG, is used now for cancers that have ...